[go: up one dir, main page]

DK2694056T3 - Terapeutisk behandling - Google Patents

Terapeutisk behandling Download PDF

Info

Publication number
DK2694056T3
DK2694056T3 DK12715421.9T DK12715421T DK2694056T3 DK 2694056 T3 DK2694056 T3 DK 2694056T3 DK 12715421 T DK12715421 T DK 12715421T DK 2694056 T3 DK2694056 T3 DK 2694056T3
Authority
DK
Denmark
Prior art keywords
therapeutic treatment
therapeutic
treatment
Prior art date
Application number
DK12715421.9T
Other languages
English (en)
Inventor
Barry Robert Davies
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK2694056T3 publication Critical patent/DK2694056T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK12715421.9T 2011-04-01 2012-04-02 Terapeutisk behandling DK2694056T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161470668P 2011-04-01 2011-04-01
PCT/GB2012/050736 WO2012131399A1 (en) 2011-04-01 2012-04-02 Therapeutic treatment

Publications (1)

Publication Number Publication Date
DK2694056T3 true DK2694056T3 (da) 2020-01-02

Family

ID=45976963

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12715421.9T DK2694056T3 (da) 2011-04-01 2012-04-02 Terapeutisk behandling

Country Status (28)

Country Link
US (2) US9402847B2 (da)
EP (2) EP2694056B1 (da)
JP (1) JP6080837B2 (da)
KR (1) KR101851820B1 (da)
CN (1) CN103442708B (da)
AU (1) AU2012235902B2 (da)
BR (1) BR112013025410A2 (da)
CA (1) CA2831848C (da)
CY (1) CY1122608T1 (da)
DK (1) DK2694056T3 (da)
EA (1) EA027506B1 (da)
ES (1) ES2761311T3 (da)
HR (1) HRP20191927T1 (da)
HU (1) HUE047357T2 (da)
IL (1) IL228589B (da)
LT (1) LT2694056T (da)
ME (1) ME03589B (da)
MX (1) MX357447B (da)
MY (1) MY169449A (da)
PH (1) PH12013502048B1 (da)
PL (1) PL2694056T3 (da)
PT (1) PT2694056T (da)
RS (1) RS59568B1 (da)
SG (1) SG193505A1 (da)
SI (1) SI2694056T1 (da)
SM (1) SMT201900725T1 (da)
WO (1) WO2012131399A1 (da)
ZA (1) ZA201308176B (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY169449A (en) * 2011-04-01 2019-04-11 Astrazeneca Ab Therapeutic treatment
KR102222346B1 (ko) * 2013-03-04 2021-03-02 아스트라제네카 아베 조합 치료
CN107670048B (zh) * 2017-08-30 2019-04-26 南京明臻医药科技有限公司 具有协同抗癌活性的中间体药物和聚乙二醇偶联协同抗癌药物、及其制备方法和应用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE637271A (da) 1963-04-04 1900-01-01
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
GB9312853D0 (en) 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
WO1997038665A2 (en) 1996-04-03 1997-10-23 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6432947B1 (en) 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
PT1023050E (pt) 1997-06-27 2013-12-04 Abraxis Bioscience Llc Novas formulações de agentes farmacológicos, métodos para a sua preparação e métodos para a sua utilização
CN1264381A (zh) 1997-08-05 2000-08-23 辉瑞产品公司 4－氨基吡咯并(3,2－d)嘧啶作为神经肽Y受体拮抗药
US6162804A (en) 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
JP2002517396A (ja) 1998-06-04 2002-06-18 アボット・ラボラトリーズ 細胞接着阻害抗炎症性化合物
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
EP1181296A1 (en) 1999-06-03 2002-02-27 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
CN100351253C (zh) 2000-06-26 2007-11-28 辉瑞产品公司 作为免疫抑制剂的吡咯并[2,3－d]嘧啶化合物
CN1308324C (zh) 2000-08-31 2007-04-04 弗·哈夫曼-拉罗切有限公司 作为α－1肾上腺素能拮抗剂的喹唑啉衍生物
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
NZ525885A (en) 2000-12-01 2005-01-28 Osi Pharm Inc Compounds specific to adenosine A1, A2A, and A3 receptor and uses as ubiquitous modulators of physiological activities
UY27220A1 (es) * 2001-03-23 2002-09-30 Aventis Pharma Sa Combinación de un taxano con una quinasa ciclina-dependiente
ES2262996T3 (es) 2002-01-07 2006-12-01 Eisai Co., Ltd. Deazapurinas y sus usos.
TW200403058A (en) 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
UA81628C2 (uk) * 2002-05-17 2008-01-25 Авентіс Фарма С.А. Застосування доцетакселу/доксорубіцину/циклофосфаміду у допоміжній терапії раку молочної залози
EP2508204B1 (en) 2002-06-26 2014-09-24 Ono Pharmaceutical Co., Ltd. Remedies for diseases caused by vascular contraction or dilation
US20040138238A1 (en) 2002-08-08 2004-07-15 Dhanoa Dale S. Substituted aminopyrimidine compounds as neurokinin antagonists
US20030139427A1 (en) 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
JP2006503826A (ja) 2002-09-06 2006-02-02 スミスクライン・ビーチャム・コーポレイション ピロロ［２，３−ｄ］ピリミジン−４−イルおよびプリン−６−イル尿素化合物
EP1567495A4 (en) 2002-11-08 2007-10-31 Harvard College SMALL, WITH TECHNETIUM-99M AND RHENIUM-MARKED MEDIUM AND METHOD OF ILLUMINATING WOVEN FABRICS, ORGANS AND TUMORS
WO2004050656A1 (ja) 2002-12-04 2004-06-17 Eisai Co., Ltd. １，３−ジヒドロ−イミダゾール縮合環化合物
EP1444982A1 (de) 2003-02-06 2004-08-11 Merckle Gmbh Verwendung von Purinderivaten als selektive Kinase-Inhibitoren
JP2006519846A (ja) 2003-03-10 2006-08-31 シェーリング　コーポレイション 複素環式キナーゼインヒビター：使用および合成の方法
EP1615926A1 (en) 2003-04-21 2006-01-18 Ustav Organicke Chemie A Biochemie Akademie Ved Ceske Republiky (purin-6-yl) amino acid and production method thereof
FR2856685B1 (fr) 2003-06-25 2005-09-23 Merck Sante Sas Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
US8362017B2 (en) 2003-08-29 2013-01-29 Exelixis, Inc. C-kit modulators and methods of use
WO2005044181A2 (en) 2003-09-09 2005-05-19 Temple University-Of The Commonwealth System Of Higher Education Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
TW200526626A (en) 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
PH12012501891A1 (en) 2003-11-21 2013-09-02 Array Biopharma Inc Akt protein kinase inhibitors
US7511159B2 (en) 2003-12-25 2009-03-31 Ono Pharmaceutical Co., Ltd. Azetidine ring compounds and drugs comprising the same
JP5213229B2 (ja) 2004-04-23 2013-06-19 エグゼリクシス， インコーポレイテッド キナーゼ調節因子および使用方法
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
ATE543821T1 (de) 2004-12-28 2012-02-15 Exelixis Inc Ä1h-pyrazoloä3,4-düpyrimidin-4-ylü-piperidin- oder piperazinverbindungen als serin-threonin- kinasemodulatoren (p70s6k, atk1 und atk2) zur behandlung von immunologischen, entzündlichen und proliferativen erkrankungen
FR2880540B1 (fr) 2005-01-13 2008-07-11 Aventis Pharma Sa Utilisation de derives de la purine comme inhibiteurs de la proteine hsp90
FR2880626B1 (fr) 2005-01-13 2008-04-18 Aventis Pharma Sa Derives de la purine, compositions les contenant et utilisation
US7423043B2 (en) 2005-02-18 2008-09-09 Lexicon Pharmaceuticals, Inc. 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds
US20060281768A1 (en) 2005-06-10 2006-12-14 Gaul Michael D Thienopyrimidine and thienopyridine kinase modulators
EP1910358A2 (en) 2005-07-14 2008-04-16 Astellas Pharma Inc. Heterocyclic janus kinase 3 inhibitors
US20070049591A1 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
AU2006284657B2 (en) 2005-08-31 2012-07-19 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
US7771751B2 (en) 2005-08-31 2010-08-10 Abraxis Bioscience, Llc Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
CA2635899A1 (en) 2006-01-19 2007-07-26 Osi Pharmaceuticals, Inc. Fused heterobicyclic kinase inhibitors
JP2009534454A (ja) 2006-04-25 2009-09-24 アステックス、セラピューティックス、リミテッド 医薬化合物
WO2007125315A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Pharmaceutical compounds
US8796293B2 (en) 2006-04-25 2014-08-05 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
JP2009536620A (ja) 2006-04-25 2009-10-15 アステックス、セラピューティックス、リミテッド 医薬組み合わせ物
US20100016340A1 (en) 2006-04-25 2010-01-21 Astex Therapeutics Limited Pharmaceutical compounds
WO2008094321A2 (en) * 2006-10-04 2008-08-07 Universtiy Of South Florida Akt sensitization of cancer cells
AR064415A1 (es) 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de pirrolo-piperidinas y purinas,composiciones farmaceuticas que los contienen y usos en trastornos y/o enfermedades mediadas por pka y pkb.
CA2673472A1 (en) 2006-12-21 2008-07-03 Vertex Pharmaceuticals Incorporated 5-cyan0-4- (pyrrolo) [2, 3b] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors
AR064416A1 (es) 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
ES2522365T3 (es) * 2007-10-11 2014-11-14 Astrazeneca Ab Derivados de pirrolo [2,3-D] pirimidina como inhibidores de proteína quinasas B
MY169449A (en) * 2011-04-01 2019-04-11 Astrazeneca Ab Therapeutic treatment

Also Published As

Publication number Publication date
US20160317540A1 (en) 2016-11-03
WO2012131399A1 (en) 2012-10-04
US9402847B2 (en) 2016-08-02
MX2013011413A (es) 2014-05-21
AU2012235902B2 (en) 2015-08-27
PT2694056T (pt) 2019-11-20
KR101851820B1 (ko) 2018-06-04
EP2694056A1 (en) 2014-02-12
JP2014509639A (ja) 2014-04-21
CY1122608T1 (el) 2021-03-12
ES2761311T3 (es) 2020-05-19
EA027506B1 (ru) 2017-08-31
NZ616410A (en) 2015-09-25
SI2694056T1 (sl) 2019-12-31
LT2694056T (lt) 2019-12-10
JP6080837B2 (ja) 2017-02-15
ZA201308176B (en) 2015-12-23
CN103442708A (zh) 2013-12-11
PL2694056T3 (pl) 2020-03-31
IL228589B (en) 2019-09-26
AU2012235902A1 (en) 2013-05-02
ME03589B (me) 2020-07-20
HUE047357T2 (hu) 2020-04-28
SG193505A1 (en) 2013-10-30
US20140121227A1 (en) 2014-05-01
CN103442708B (zh) 2016-11-09
PH12013502048A1 (en) 2013-12-16
MY169449A (en) 2019-04-11
HRP20191927T1 (hr) 2020-01-10
EP3620159A1 (en) 2020-03-11
CA2831848A1 (en) 2012-10-04
IL228589A0 (en) 2013-12-31
PH12013502048B1 (en) 2018-07-11
EA201391327A1 (ru) 2014-03-31
KR20140022856A (ko) 2014-02-25
CA2831848C (en) 2020-12-22
RS59568B1 (sr) 2019-12-31
SMT201900725T1 (it) 2020-01-14
MX357447B (es) 2018-07-10
EP2694056B1 (en) 2019-10-16
BR112013025410A2 (pt) 2016-12-20

Similar Documents

Publication Publication Date Title
EP2663304A4 (en) COMBINATION THERAPY
LT2707030T (lt) Vėžio gydymas
EP2864360A4 (en) TARGETED THERAPEUTICS
HUE046667T2 (hu) Rák kombinatív kezelése
BR112014007603A2 (pt) métodos de tratamento do câncer
CO7020866A2 (es) Péptidos terapéuticos
PL2739153T3 (pl) Leczenie raka sutka
EP2906208A4 (en) THERAPEUTIC TREATMENT
EP2726095A4 (en) COMBINATION THERAPY
DK2760886T3 (da) Immunocytokin-kombinationsterapi
FI20115876A0 (fi) Yhdistelmähoito
DK2489413T3 (da) Behandlingsapparat
DK2783256T3 (da) Terapeutiske briller
PT2750709T (pt) Tratamento da caquexia
EP2780012A4 (en) Methods of treatment with deferiprone
IL229081A0 (en) Isoxazolines as therapeutic agents
CO6880064A2 (es) Métodos terapéuticos
FI20115640A0 (fi) Yhdistelmähoito
PL2780003T3 (pl) Leczenie niedoczynności kory nadnerczy
IL228729A0 (en) Treatment regimens
EP2688566A4 (en) THERAPEUTIC AGENTS AGAINST CANCER
DK2694056T3 (da) Terapeutisk behandling
FI20115020A0 (fi) Käsittely-yksikkö
FI20115905A0 (fi) Käsittelyjärjestely
DK2663304T3 (da) Kombinationsterapi